PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
Status:
Completed
Trial end date:
2019-05-07
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I study is to investigate the pharmacokinetic properties of
ticagrelor in pediatric patients from 0 to less than 24 months with sickle cell disease.
Ticagrelor dose level adjustment will require a Protocol amendment and regulatory approval.